AMHC SEC filings, in plain English
Everything Amplitude Healthcare Acquisition Corp has filed with the SEC that we hold — 40 filings, newest first, 9 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Jasper Therapeutics, Inc. filed an 8-K on August 26, 2026, reporting that it received a notice from Nasdaq on August 21, 2026, stating the company no longer satisfies the minimum stockholders' equity requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1), based on its Quarterly Report on Form 10-Q for the period ended June 30, 2026. The filing states the notice has no immediate effect on listing but requires the company to submit a compliance plan by October 5, 2026. The company anticipates regaining compliance through stockholder approval of the conversion of outstanding Non-Voting Convertible Preferred Stock at a special meeting. Why it matters: This filing signals a potential delisting risk for Jasper Therapeutics (JSPR) due to failing the $2.5 million stockholders' equity standard. While the SPAC AMHC is closed, this event impacts the post-merger entity's trading status and liquidity. The outcome depends on whether Nasdaq accepts the compliance plan and whether stockholders approve the preferred stock conversion; failure could lead to suspension or delisting, though the company expects to request a hearing if necessary.
What changed: The 10-Q filed under Commission file number 001-39138 is that of Jasper Therapeutics, Inc. (Nasdaq: JSPR, with ten warrants exercisable for one share at $115.00) for the quarter ended June 30, 2026. Cash and equivalents were $7,314 thousand against $28,692 thousand at December 31, 2025 and total assets $11,802 thousand against $35,779 thousand. Total liabilities fell to $10,389 thousand from $31,628 thousand, driven by the warrant liability dropping to $2,544 thousand from $16,164 thousand, and stockholders' equity was $1,413 thousand. Why it matters: Cash fell by $21.4 million over six months while the reported loss shrank by $44 million — the loss improvement is mostly a warrant revaluation and a four-fifths cut in R&D spend, not cash generation. Equity of $1.4 million sits against $7.8 million of current liabilities.
going-concern doubt, mandate languagenothing moved · 2 with no prior record of ours
- Going-concern doubt
- stated · unchanged
- Mandate language
- we are focusing on advancing a portfolio of clinical program…not matched in this filing
The clause …“31, 2026 or for any other interim period or for any other future year. 5 Going Concern In accordance with Accounting Standards Codification (“ASC”) Topic 205-40, Going Concern, the Company evaluated whether there are conditions and”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Jasper Therapeutics, Inc. issued a press release dated August 14, 2026 reporting second quarter 2026 results and a corporate update. It states that on July 16, 2026 Jasper completed the all-stock acquisition of Kira Pharmaceuticals and, concurrently, entered a securities purchase agreement for non-voting convertible preferred stock in a private placement co-led by Affinity Asset Advisors and Ikarian Capital that produced total gross proceeds of approximately $132 million. Why it matters: The $132 million closed in July, after the June 30 balance-sheet date, so the $7.3 million cash figure and the runway-to-2028 statement describe two different moments. The preferred stock is non-voting and its conversion requires a shareholder vote that has not happened, so the dilution it represents is contingent on that approval.
What changed: 8-K of Jasper Therapeutics, Inc. Item 5.07 (submission of matters to a vote): at the 2026 Annual Meeting on July 31, 2026, 21,121,396 shares, about 75% of the 28,009,802 voting common shares outstanding on the June 5, 2026 record date, were represented. Proposal 1 elected Class II directors Judith Shizuru (9,273,875 for, 419,763 withheld) and Tom Wiggans (9,280,610 for, 413,028 withheld), each with 11,427,758 broker non-votes. Proposal 2 ratified PricewaterhouseCoopers LLP 20,635,404 to 434,262. Proposal 3, advisory say-on-pay, passed 9,016,797 to 604,173. Why it matters: Routine annual-meeting results. The report says stockholders considered four proposals but the document gives voting results for three, so the fourth proposal's outcome is not stated in this filing. Broker non-votes of 11,427,758 exceed the votes cast for the directors, so the discretionary proposal drew far more shares than the contested ones.
What changed: 8-K of Jasper Therapeutics, Inc. Item 8.01 (other events): sets out the terms of the contingent value rights issued in the July 16, 2026 acquisition of Kira Pharmaceuticals under the merger agreement of the same date. Each holder of voting common stock of record immediately prior to the Effective Time receives one CVR per share. Each CVR entitles its holder to a pro rata portion of a $30.0 million Milestone Payment if the FDA issues a Priority Review Voucher in connection with briquilimab on or prior to December 31, 2028. The CVR record date was July 16, 2026, the closing date. Why it matters: The CVRs are not transferable except in limited circumstances, are not certificated, and will not be registered with the SEC or listed on any exchange, so a holder cannot sell the claim. If the milestone is met by the Expiration Date but no Monetization Event has occurred, the CVRs do not expire and the payment falls due 90 days after that event; on a Change of Control the payment comes at the earlier of consummation or 90 days after monetization.
What changed: Jasper Therapeutics, Inc., the successor to Amplitude Healthcare Acquisition Corporation, filed as Exhibit 2.1 an Agreement and Plan of Merger dated July 16, 2026 among Jasper Therapeutics, Kira Holdco Inc. and Kira Pharmaceuticals, a Cayman Islands exempted company. The agreement covers the merger and effective time, merger consideration and conversion of company shares, treatment of equity awards and company SAFEs, appraisal rights, a calculation of Parent Net Cash, and a Contingent Value Right. Why it matters: Two structural features stand out for a former AMHC holder. A Parent Net Cash calculation means the exchange ratio flexes with how much cash Jasper actually has at closing, so continued burn between signing and closing directly reduces what existing holders keep. A Contingent Value Right means part of the consideration is deferred and conditional rather than paid in shares up front. The excerpt is the agreement's structure rather than its numbers, so the ratio and ownership split must be read from the merger consideration section itself.
What changed: Jasper Therapeutics (Nasdaq: JSPR), the Amplitude Healthcare Acquisition successor, announced on July 16, 2026 that it completed the all-stock acquisition of Kira Pharmaceuticals, a Cayman developer of complement therapies. Concurrently it signed a securities purchase agreement for non-voting convertible preferred stock in a private placement co-led by Affinity Asset Advisors and Ikarian Capital with Columbia Threadneedle, Balyasny, Mirador and others, expected to yield about $132 million gross. Kira out-licensed KP-301 and KP-402 to Mirador for $12 million on signing plus milestones. Why it matters: The financing is the operative fact: roughly $132 million of new preferred plus $12 million of upfront licensing cash is stated to fund the combined company through the second half of 2028, which converts a cash-constrained de-SPAC into one with a multi-year runway. The cost is dilution — an all-stock acquisition plus non-voting convertible preferred means existing JSPR holders are diluted twice, once by Kira's shareholders and again on conversion of the preferred at whatever terms the purchase agreement sets.
What changed: Jasper Therapeutics, Inc. (successor to SPAC Amplitude Healthcare Acquisition Corp) called its 2026 annual meeting for Friday, July 31, 2026 at 10:00 a.m. Pacific Time by live webcast, record date June 5, 2026. The proxy discloses 2025 general and administrative expenses of $20.8 million including $4.7 million of stock-based compensation and a net loss of $75.8 million, or $3.95 per basic and diluted share. Effective January 5, 2026 Mr. Wiggans became Executive Chairperson concurrently with the appointment of Mr. Mahal as Chief Executive Officer and President. Why it matters: Routine annual governance, but the financials define the risk: a $75.8 million net loss in 2025 against a share count implied by the $3.95 loss per share of roughly 19 million shares means the company burns far more each year than a small-cap equity base can absorb without repeated dilutive financings. A simultaneous CEO change and elevation of the chairman to an executive role in January 2026 signals a strategic reset. Legacy Amplitude SPAC holders have no trust claim; their downside is the full equity risk of a clinical-stage biotech.
What changed: Jasper Therapeutics, Inc. filed as definitive additional materials the notice of internet availability of proxy materials for its 2026 Annual Meeting of Stockholders, to be held virtually on Friday, July 31, 2026 at 10:00 a.m. Pacific Time. Three proposals are listed: election of two Class II directors to serve until the 2029 annual meeting; ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026; and an advisory vote on the compensation of the named executive officers. Why it matters: The notice is expressly not a ballot and adds no substantive terms; it directs holders to the proxy materials and sets the mechanics — a 12-digit control number to vote electronically during the virtual meeting, and a July 17, 2026 request-by date for a paper or e-mail copy of the materials in time for delivery. Nothing here touches trust, redemption or a business-combination deadline, so its one load-bearing datum for a calendar is the July 31, 2026 meeting date. The substantive disclosure sits in the proxy statement and the fiscal 2025 Form 10-K the notice points to.
mandate language, going-concern doubtnothing moved · 2 with no prior record of ours
- Mandate language
- not previously extractedwe are focusing on advancing a portfolio of clinical program…
- Going-concern doubt
- stated · unchanged
The clause “December 31, 2026 or for any other interim period or for any other future year. Going Concern In accordance with Accounting Standards Codification (“ASC”) Topic 205-40, Going Concern , the Company evaluated whether there are conditions”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
going-concern doubt, mandate languagenothing moved · 2 with no prior record of ours
- Going-concern doubt
- stated · unchanged
- Mandate language
- we are focusing on advancing a portfolio of clinical program… · unchanged
The clause …“net losses and negative operating cash flows since our inception which raises substantial doubt about our ability to continue as a going concern. We expect to incur net losses for the foreseeable future and may never achieve or maintain”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.